Technical analysis of Organon & Co. (OGN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
Price Performance
| 1 month | -0.07% |
| 3 months | +1.79% |
| Year-to-date | +90.66% |
| 1 year | +30.81% |
| 3 years | -29.75% |
| 5 years | -59.83% |
52-Week Range
| 52-week High | $13.79 |
| 52-week Low | $5.69 |
| Avg Volume (90d) | 2.9M |
Technical Indicators
| SMA 50 | $13.63 |
| SMA 200 | $10.50 |
| Beta | 0.64 |
| 30-day Volatility (annualised) | 3.1% |
| Price vs SMA 50 | +0.3% |
| Price vs SMA 200 | +30.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.75 | |
| 2025-11 | $7.71 | +14.2% |
| 2025-12 | $7.17 | -7.0% |
| 2026-01 | $8.54 | +19.1% |
| 2026-02 | $7.29 | -14.6% |
| 2026-03 | $5.99 | -17.8% |
| 2026-04 | $13.25 | +121.2% |
| 2026-05 | $13.34 | +0.7% |
| 2026-06 | $13.54 | +1.5% |
| 2026-07 | $13.55 | +0.1% |
| 2026-08 | $13.76 | +1.5% |
| 2026-09 | $13.67 | -0.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $13.67 |
| Market Cap | $3.6B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 17.31 |
| Price / Book | 3.57 |
| EV / EBITDA | 7.87 |
| Dividend Yield | 0.59% |
Financial Health
| Debt / Equity | 8.50 |
| Current Ratio | 1.95 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.21 |